Gmax Biopharm Australia Pty Ltd.   Report issue

For profit Phase 1
Founded: Hangzhou China (2010)

Organization Overview

First Clinical Trial
2020
NCT04503733
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Gmax Biopharm Australia Pty Ltd. | Gmax Biopharm LLC.

Active Ingredients

Drugs in Phase 1 Trials (2)

Getagozumab (2 trials)

gma106 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 1)

Hypertension (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2